Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy

Overview

Journal Vaccines (Basel)

Date 2015 Sep 10

PMID 26350600

Citations 100

Authors

Yuchen Fan

James J Moon

Affiliations

Soon will be listed here.

Abstract

Recent studies have demonstrated great therapeutic potential of educating and unleashing our own immune system for cancer treatment. However, there are still major challenges in cancer immunotherapy, including poor immunogenicity of cancer vaccines, off-target side effects of immunotherapeutics, as well as suboptimal outcomes of adoptive T cell transfer-based therapies. Nanomaterials with defined physico-biochemical properties are versatile drug delivery platforms that may address these key technical challenges facing cancer vaccines and immunotherapy. Nanoparticle systems have been shown to improve targeted delivery of tumor antigens and therapeutics against immune checkpoint molecules, amplify immune activation via the use of new stimuli-responsive or immunostimulatory materials, and augment the efficacy of adoptive cell therapies. Here, we review the current state-of-the-art in nanoparticle-based strategies designed to potentiate cancer immunotherapies, including cancer vaccines with subunit antigens (e.g., oncoproteins, mutated neo-antigens, DNA and mRNA antigens) and whole-cell tumor antigens, dendritic cell-based vaccines, artificial antigen-presenting cells, and immunotherapeutics based on immunogenic cell death, immune checkpoint blockade, and adoptive T-cell therapy.

Citing Articles

Recent advances in the bench-to-bedside translation of cancer nanomedicines.

Liu Y, Zhang Y, Li H, Hu T Acta Pharm Sin B. 2025; 15(1):97-122.

PMID: 40041906 PMC: 11873642. DOI: 10.1016/j.apsb.2024.12.007.

and gastric cancer: current insights and nanoparticle-based interventions.

Shah S, Mumtaz M, Sharif S, Mustafa I, Nayila I RSC Adv. 2025; 15(7):5558-5570.

PMID: 39967885 PMC: 11834156. DOI: 10.1039/d4ra07886a.

Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects.

Jiang Y, Wang C, Zu C, Rong X, Yu Q, Jiang J Int J Nanomedicine. 2024; 19:9459-9486.

PMID: 39371481 PMC: 11456300. DOI: 10.2147/IJN.S466396.

Double-layered protein nanoparticles conjugated with truncated flagellin induce improved mucosal and systemic immune responses in mice.

Kim J, Zhu W, Dong C, Wei L, Ma Y, Denning T Nanoscale Horiz. 2024; 9(11):2016-2030.

PMID: 39240547 PMC: 11493517. DOI: 10.1039/d4nh00287c.

Ferritin Nanoparticle Delivery of the E2 Protein of Classical Swine Fever Virus Completely Protects Pigs from Lethal Challenge.

Zhong D, Lu Z, Xia Y, Wu H, Zhang X, Li M Vaccines (Basel). 2024; 12(6).

PMID: 38932358 PMC: 11209039. DOI: 10.3390/vaccines12060629.

References

Roeven M, Hobo W, van der Voort R, Fredrix H, Norde W, Teijgeler K . Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18. J Immunother. 2015; 38(4):145-54. DOI: 10.1097/CJI.0000000000000071. View

Fox C, Sivananthan S, Duthie M, Vergara J, Guderian J, Moon E . A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7. J Nanobiotechnology. 2014; 12:17. PMC: 4014409. DOI: 10.1186/1477-3155-12-17. View

Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz G, Li J, Mottram P . Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004; 173(5):3148-54. DOI: 10.4049/jimmunol.173.5.3148. View

Pradhan P, Qin H, Leleux J, Gwak D, Sakamaki I, Kwak L . The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials. 2014; 35(21):5491-504. PMC: 4747034. DOI: 10.1016/j.biomaterials.2014.03.039. View

Rosalia R, Cruz L, van Duikeren S, Tromp A, Silva A, Jiskoot W . CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2014; 40:88-97. DOI: 10.1016/j.biomaterials.2014.10.053. View

Muraoka D, Harada N, Hayashi T, Tahara Y, Momose F, Sawada S . Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity. ACS Nano. 2014; 8(9):9209-18. DOI: 10.1021/nn502975r. View

Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautes-Fridman C, Galon J . Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology. 2013; 2(9):e25595. PMC: 3850274. DOI: 10.4161/onci.25595. View

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J . Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015; 520(7549):692-6. PMC: 4838069. DOI: 10.1038/nature14426. View

10.

Downey S, Klapper J, Smith F, Yang J, Sherry R, Royal R . Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007; 13(22 Pt 1):6681-8. PMC: 2147083. DOI: 10.1158/1078-0432.CCR-07-0187. View

11.

Xiao X, Gong W, Demirci G, Liu W, Spoerl S, Chu X . New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol. 2011; 188(2):892-901. PMC: 3262989. DOI: 10.4049/jimmunol.1101373. View

12.

Vacchelli E, Galluzzi L, Fridman W, Galon J, Sautes-Fridman C, Tartour E . Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012; 1(2):179-188. PMC: 3376992. DOI: 10.4161/onci.1.2.19026. View

13.

Wilson J, Keller S, Manganiello M, Cheng C, Lee C, Opara C . pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano. 2013; 7(5):3912-25. PMC: 4042837. DOI: 10.1021/nn305466z. View

14.

Sahdev P, Ochyl L, Moon J . Biomaterials for nanoparticle vaccine delivery systems. Pharm Res. 2014; 31(10):2563-82. PMC: 4198431. DOI: 10.1007/s11095-014-1419-y. View

15.

Wang X, Li S, Shi Y, Chuan X, Li J, Zhong T . The development of site-specific drug delivery nanocarriers based on receptor mediation. J Control Release. 2014; 193:139-53. DOI: 10.1016/j.jconrel.2014.05.028. View

16.

Rahimian S, Kleinovink J, Fransen M, Mezzanotte L, Gold H, Wisse P . Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8(+) T cell immune response. Biomaterials. 2014; 37:469-77. DOI: 10.1016/j.biomaterials.2014.10.043. View

17.

de Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, van der Vlies A . Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A. 2013; 110(49):19902-7. PMC: 3856841. DOI: 10.1073/pnas.1313152110. View

18.

Sunshine J, Perica K, Schneck J, Green J . Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials. 2013; 35(1):269-277. PMC: 3902087. DOI: 10.1016/j.biomaterials.2013.09.050. View

19.

Kaczanowska S, Mary Joseph A, Davila E . TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013; 93(6):847-63. PMC: 3656332. DOI: 10.1189/jlb.1012501. View

20.

Silva J, Videira M, Gaspar R, Preat V, Florindo H . Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release. 2013; 168(2):179-99. DOI: 10.1016/j.jconrel.2013.03.010. View